Biotie Gears Up For New Pivotal Trial Of Tozadenant In Parkinson’s
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
With the goal of introducing the first adenosine A2a antagonist for Parkinson’s disease in North America and Europe, Biotie plans to start a Phase III study of tozadenant in almost 900 Parkinson’s patients this summer.